Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway
Sign Up to like & getrecommendations! Published in 2020 at "Acta Pharmacologica Sinica"
DOI: 10.1038/s41401-020-0418-2
Abstract: Glioblastoma (GBM) patients have extremely poor prognoses, and currently no effective treatment available including surgery, radiation, and chemotherapy. MAPK-interacting kinases (MNK1/2) as the downstream of the MAPK-signaling pathway regulate protein synthesis in normal and tumor… read more here.
Keywords: glioblastoma; gbm; gbm cells; pathway ... See more keywords
Phase I study of apatinib combined with docetaxel in EGFR-negative advanced non-small cell lung cancer (NSCLC).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e21184
Abstract: e21184Background: Chemotherapy combined with antiangiogenic agents such as bevacizumab and ramucirumab has been shown to bring overall survival benefit for advanced NSCLC patients (pts). Apatinib i... read more here.
Keywords: apatinib combined; combined docetaxel; docetaxel egfr; study apatinib ... See more keywords